Myriad Genetics Inc (MYGN)

Assess today's live Myriad Genetics Inc (MYGN) share price, performance and insights using our live NASDAQ: MYGN stock exchange data.

Analyse the historical data and Myriad Genetics Inc share price performance charts on this page. Our technical summary section provides analysis on Myriad Genetics share price buy/sell indicators using real-time data (or discuss the Myriad Genetics (MYGN) stock price today with other investors in the Myriad Genetics NASDAQ share price and sentiment chat forum).

Use the dropdown to select a relevant stock exchange for the current NASDAQ MYGN share price (ISIN: US62855J1043) to enhance your trading decisions with our free investment tools and resources.

What Is the Myriad Genetics Inc Share Price Today?
The Myriad Genetics share price today is 15.13.

What Is the Stock Symbol for Myriad Genetics Inc
The stock symbol (or 'ticker') for Myriad Genetics Inc is "MYGN."

What Stock Exchange Does Myriad Genetics Inc Trade On?
Myriad Genetics Inc is listed and trades on the NASDAQ stock exchange.

Is Myriad Genetics Inc a Good Stock to Buy?
Determining whether Myriad Genetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.